Gynaecological Oncology
of lymph node dissection in endometrial adenocarcinoma: a surveillance, epidemiology, and end results analysis, Int J Gynecol Cancer, 2008;18(2):255–61.
31. Barton DP, Naik R, Herod J, Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC Trial): A randomized study, Int J Gynecol Cancer, 2009;19(8): 1465.
32. Ben-Shachar I, Pavelka J, Cohn DE, et al., Surgical staging for patients presenting with grade 1 endometrial carcinoma, Obstet Gynecol, 2005;105(3):487–93.
33. Niikura H, Okamura C, Utsunomiya H, et al., Sentinel lymph node detection in patients with endometrial cancer, Gynecol Oncol, 2004;92(2):669–74.
34. Burke TW, Levenback C, Tornos C, et al., Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study, Gynecol Oncol, 1996;62(2):169–73.
35. Lewis BV, Stallworthy JA, Cowdell R, Adenocarcinoma of the body of the uterus, J Obstet Gynaecol Br Commonw, 1970;77(4):343–8.
36. Boronow RC, Morrow CP, Creasman WT, et al., Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study, Obstet Gynecol, 1984;63(6):825–32.
37. Larson DM, Johnson KK, Pelvic and para-aortic lymphadenectomy for surgical staging of high-risk endometrioid adenocarcinoma of the endometrium, Gynecol Oncol, 1993;51(3):345–8.
38. Kim YB, Niloff JM, Endometrial carcinoma: analysis of recurrence in patients treated with a strategy minimizing lymph node sampling and radiation therapy, Obstet Gynecol, 1993;82(2):175–80.
39. Mariani A, Keeney GL, Aletti G, et al., Endometrial carcinoma: paraaortic dissemination, Gynecol Oncol, 2004;92(3):833–8.
40. Mariani A, Dowdy SC, Cilby WA, et al., Prospective
assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging, Gynecol Oncol, 2008;109(1):11–18.
41. Tanaka H, Sato H, Miura H, et al., Can we omit para-aorta lymph node dissection in endometrial cancer?, Jpn J Clin Oncol, 2006;36(9):578–81.
42. Fujimoto T, Nanjyo H, Nakamura A, et al., Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer, Gynecol Oncol, 2007;107(2):253–9.
43. Mariani A, Dowdy SC, Podratz KC, New surgical staging of endometrial cancer: 20 years later, Int J Gynaecol Obstet, 2009;105(2):110–11.
44. Chan JK, Urban R, Cheung MK, et al., Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients, Cancer, 2007;109(12):2454–60.
45. Lutman CV, Havrilesky LJ, Cragun JM, et al., Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology, Gynecol Oncol, 2006;102(1):92–7.
46. Everett E, Tamimi H, Greer B, et al., The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer, Gynecol Oncol, 2003;90(1):150–57.
47. Mariani A, Webb MJ, Galli L, et al., Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer, Gynecol Oncol, 2000;76(3):348–56.
48. Abu-Rustum NR, Alektiar K, Iasonos A, et al., The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center, Gynecol Oncol, 2006;103(2):714–18.
49. Orr JW Jr, Holimon JL, Orr PF, Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol, 1997;176(4): 77–88, discussion 788–9.
50. Santi A, Kuhn A, Gyr T, et al., Laparoscopy or laparotomy? A comparison of 240 patients with early-stage endometrial cancer, Surg Endosc, 2010;24(4):939–43.
51. Holloway RW, Ahmad S, DeNardis SA, et al., Robotic-assisted laparoscopic hysterectomy and lymphadenectomy for endometrial cancer: Analysis of surgical performance, Gynecol Oncol, 2009;115(3):447–52.
52. Keys HM, Roberts JA, Brunetto VL, et al., A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, 2004;92(3):744–51.
53. ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, et al., Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis, Lancet, 2009;373(9658):137–46.
54. Obermair A, Cheuk R, Pak SC, et al., Disease-free s urvival after vaginal vault brachytherapy versus observation for patients with node-negative intermediate-risk endometrial adenocarcinoma, Gynecol Oncol, 2008;110(3):280–85.
55. Eltabbakh GH, Piver MS, Hempling RE, et al., Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial, Int J Radiat Oncol Biol Phys, 1997;38(2):373–80.
56. Belinson JL, Lee KR, Badger GJ, et al., Clinical stage I adenocarcinoma of the endometrium–analysis of recurrences and the potential benefit of staging lymphadenectomy, Gynecol Oncol, 1992;44(1):17–23.
57. PORTEC, PORTEC 3, 2010. Available at:
www.clinical
research.nl/portec3/ (accessed 14 June 2010).
46
EUROPEAN OBSTETRICS & GYNAECOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68